Your browser doesn't support javascript.
loading
Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.
Arroyo-Andrés, Jorge; Agud-Dios, Manuel; Rubio-Muniz, Carmen A; Vico-Alonso, Cristina; Cortijo-Cascajares, Susana; Ortiz-Romero, Pablo L.
Afiliação
  • Arroyo-Andrés J; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
  • Agud-Dios M; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
  • Rubio-Muniz CA; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
  • Vico-Alonso C; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
  • Cortijo-Cascajares S; Pharmacy Department, 12 de Octubre University Hospital, Madrid, Spain.
  • Ortiz-Romero PL; Department of Dermatology, 12 de Octubre Hospital, Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain.
Int J Dermatol ; 61(7): e267-e269, 2022 07.
Article em En | MEDLINE | ID: mdl-34363613

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Anaplásico de Células Grandes / Imunoconjugados / Brentuximab Vedotin Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Int J Dermatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Anaplásico de Células Grandes / Imunoconjugados / Brentuximab Vedotin Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Int J Dermatol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha